rrd182292_205760.html

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KWO/Z11WlYHz8mk8xvB0IXsry3FOvsiLX+6WXpfWJIoBEdiT2LXqeZZLKJBZn2tT LoiUjfqHmg+t1pIFGz+SWA== 0001181431-08-038738.txt : 20080613 0001181431-08-038738.hdr.sgml : 20080613 20080613182801 ACCESSION NUMBER: 0001181431-08-038738 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20080612 FILED AS OF DATE: 20080613 DATE AS OF CHANGE: 20080613 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OSCIENT PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0000356830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042297484 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1000 WINTER STREET STREET 2: SUITE 2200 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 7813982300 MAIL ADDRESS: STREET 1: 1000 WINTER STREET STREET 2: SUITE 2200 CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: GENOME THERAPEUTICS CORP DATE OF NAME CHANGE: 19941215 FORMER COMPANY: FORMER CONFORMED NAME: COLLABORATIVE RESEARCH INC DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Leone John R CENTRAL INDEX KEY: 0001301047 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-10824 FILM NUMBER: 08899144 BUSINESS ADDRESS: BUSINESS PHONE: 201-804-3000 MAIL ADDRESS: STREET 1: ONE MEADOWLANDS PLAZA CITY: EAST RUTHERFORD STATE: NJ ZIP: 07073 4 1 rrd204058.xml FORM 4 X0202 4 2008-06-12 0 0000356830 OSCIENT PHARMACEUTICALS CORP OSCI 0001301047 Leone John R 1000 WINTER STREET SUITE 2200 WALTHAM MA 02451 1 0 1 0 Common Stock 2008-06-12 4 A 0 300 0 A 900 D Common Stock 1388889 I See Footnote Common Stock Options (right to buy) 1.77 2008-06-12 4 A 0 750 0 A 2018-06-11 Common Stock 750 750 D Restricted Shares issued under the Company's 2001 Incentive Plan and vest in equal annual installments over two years. The shares are deemed to be beneficially owned by Paul Royalty Fund Holdings II ("PRFH"), Paul Royalty Fund II, LP ("PRF"), Paul Royalty Associates II, LP ("PRA"), Paul Royalty Management, LLC ("PRM"), Paul Capital Advisors, LLC ("PCA"). PRFH directly owns 1,388,889 shares of Common Stock. PRF and PRA may be deemed to indirectly own 1,388,889 shares of common stock held by PRFH because PRF and PRA are the general partners of PRFH. PRM may be deemed to indirectly own the shares because PRM is the general partner of PRF and PRA. As manager of PRA, PCA exercises voting and dispositive power over investments held by PRA. The Reporting Person is a member of PCA, which has voting and dispositive control over the shares. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Stock Options issued under the Company's 2001 Incentive Plan and vest in equal quarterly installments over two years. Stanley F. Chalvire, Esq., Corporate Attorney 2008-06-13 EX-99. 2 rrd182292_205760.htm POWER OF ATTORNEY rrd182292_205760.html

POWER OF ATTORNEY

I hereby constitute and appoint each of Robert E. Farrell, Jr. and Stanley F. Chalvire, Esq.,
signing singly, my true and lawful attorney-in-fact to:

(1) execute for and on my behalf, in my capacity as a director of Oscient Pharmaceuticals
Corporation (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the
Securities Exchange Act of 1934 and the rules thereunder;

(2) do and perform any and all acts for and on my behalf that may be necessary or desirable
to complete and execute any such Form 3, 4 or 5 and timely file such form with the
United States Securities and Exchange Commissi on and any stock exchange or similar
authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in
the opinion of such attorney-in-fact, may be to my benefit, in my best interest, or that I
am legally required to do, it being understood that the documents executed by such
attorney-in-fact's discretion.

I hereby grant to each such attorney-in-fact full power and authority to do and perform
any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise
of any of the rights and powers herein granted, as fully to all intents and purposes as I might or
could do if personally present, with full power of substitution or revocation, hereby ratifying and
confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of att orney and the rights and powers
herein granted. I acknowledge that the attorneys-in-fact, in serving in such capacity at my
request, are not assuming, nor is the Company assuming, any of my responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until I am no longer required
to file Forms 3, 4 and 5 with respect to my holdings of and transactions in Company securities,
unless I earlier revoke it in a signed writing delivered to the attorneys-in-fact.

IN WITNESS WHEREOF, I have caused this Power of Attorney to be executed as of this
December 5, 2007.

                                        _/s/ John R. Leone________________________
                                               John R. Leone
                                        Director

-----END PRIVACY-ENHANCED MESSAGE-----